Weekly Diabetes Insulin
FDA Approves Eli Lilly's Once-Weekly Insulin to Simplify Diabetes Treatment
Anonymous
Key Points
1
Lilly says Onswik is designed to deliver steady basal insulin levels over seven days.
2
Reported common side effects include low blood sugar and weight gain.
3
The reduction in injection frequency describes dosing convenience; it does not indicate a difference in safety or effectiveness.
4
Onswik had already received regulatory approval in Europe, Japan and Mexico; the FDA also approved Novo Nordisk’s competing weekly insulin Awiqli in March.
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a shift toward less frequent injections. Medscape reports the drug works alongside diet and exercise to control blood sugar. Lilly says patients could get more than 300 fewer injections per year compared to daily insulin treatment.
In four late-stage trials with over 3,400 people, Onswik reduced A1C levels — a key diabetes marker — just as well as daily basal insulins. Endpoints News notes the approval sets up direct competition with Novo Nordisk's Awiqli, another weekly insulin approved by the FDA in March. The prefilled KwikPen will arrive in the U.S. soon in two dose strengths.
How Onswik Delivers Week-Long Insulin Coverage
Onswik is designed to deliver steady basal insulin over seven days. Hoodline explains it provides consistent blood sugar control without daily injections. The drug comes as a prefilled pen that patients inject once per week, making it easier to remember doses than traditional daily insulin regimens.
Common Side Effects Include Low Blood Sugar and Weight Gain
Like all insulins, Onswik carries risks. The most reported side effects are low blood sugar and weight gain. NY Post notes that low blood sugar can be serious, though Onswik should not be used by people with type 1 diabetes because of the risk of severe hypoglycemia. Patients need to monitor their blood sugar closely when starting the drug.
Onswik Joins Global Market With Weekly Dosing Advantage
Benzinga reports Onswik had already won approval in Europe, Japan, and Mexico before the FDA decision. The once-weekly schedule makes it stand out from daily basal insulins. However, the reduced injection frequency does not mean the drug is safer or more effective — it simply offers more convenience for patients who struggle to remember daily doses.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
123
Reach
144
A
AnonymousAuthor
